Skip to content
Menu

Incannex Healthcare Inc. IXHL

Full chart Compare
Set alert

Price alert · IXHL

All alert types
1.74 USD -0.01 (-0.57%)

Regular-session close

1.74 0.00 0.00%

After hours · Nov 19, 4:00 PM ET

1.74 Day range 2.04
1.61 52-week range 14.91
YTD
-83.80%
1 year
-82.58%

5D -0.03 (-1.52%)

1.601.802FriMonTueWedThu1.95
Market cap
21.83M
Revenue (ttm)
12.00K
EPS (ttm)
-1.25
Shares out
17.64M
Forward P/E
-0.86
YTD return
-83.80%
1-year return
-82.58%
Volume
192.50K
Avg volume
87.43K
Open
1.76
Previous close
1.75
Day's range
1.74 – 2.04
52-week range
1.61 – 14.91
Beta
2.21

Key statistics

50-day average
2.08
200-day average
2.40
Enterprise value
29.80M
Price / sales
2469.99
Price / book
2.64
Free cash flow
-9.32M
Total cash
5.86M
Total debt
373.00K
Return on equity
-115.22%
Short % of float
0.37%

Fundamental scorecard

5 of 25 checks passed on IXHL’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
IXHL Revenue — quarterly 0
IXHL Net income — quarterly -1.94M
IXHL EPS — quarterly -0.15

Earnings

IXHL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 12, 2025Dec 1, 20240.00———
Sep 30, 2024Jun 1, 20240.00-0.39——

About Incannex Healthcare Inc.

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Australia
Website
incannex.com

News

Your note

Sign in to keep a note on IXHL — it syncs with the Stock Master app.

Insider holders

IXHL insider holders
InsiderRelationLatest transactionDateShares held
ANASTASSOV GEORGEDirectorStock Award(Grant)Dec 20, 2023769,721
CLARK ROBERTDirectorStock Award(Grant)Dec 20, 2023100,000
LATHAM JOELChief Executive OfficerStock Award(Grant)Dec 20, 20231,577,480
SWAN JOSEPHOfficerStock Award(Grant)Oct 22, 2024100,476
VALENTINE TROY ROBERTDirectorStock Award(Grant)Dec 20, 20231,036,510
WIDDOWS PETERDirectorStock Award(Grant)Dec 20, 2023270,847

Institution ownership

IXHL institution ownership
Holder% heldSharesValueReported
Tidal Investments, LLC0.74%130,026218.44KSep 29, 2024
AdvisorShares Investments, LLC0.72%126,990213.34KSep 29, 2024
Morgan Stanley0.22%38,85365.27KSep 29, 2024
Virtu Financial LLC0.21%36,62261.52KSep 29, 2024
Bridgeway Capital Management, Inc.0.14%25,00042.00KSep 29, 2024
Citadel Advisors Llc0.14%24,15240.58KSep 29, 2024

Fund ownership

IXHL fund ownership
Holder% heldSharesValueReported
AdvisorShares Trust-AdvisorShares Psychedelics ETF0.81%142,545239.47KOct 30, 2024
Amplify ETF Tr-Amplify Alternative Harvest ETF0.74%130,026218.44KSep 29, 2024
Bridgeway Funds Inc-Ultra Small Company Market Fund0.14%25,00042.00KSep 29, 2024
Fidelity NASDAQ Composite Index Fund0.05%7,96313.38KOct 30, 2024